1529 related articles for article (PubMed ID: 10896249)
1. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
2. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
3. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
[TBL] [Abstract][Full Text] [Related]
4. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
Matzdorff A; Voss R
Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
7. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
8. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
Marciniak SJ; Mascelli MA; Furman MI; Michelson AD; Jakubowski JA; Jordan RE; Marchese PJ; Frelinger AL
Thromb Haemost; 2002 Jun; 87(6):1020-5. PubMed ID: 12083481
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
Schneider DJ; Taatjes DJ; Sobel BE
Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
[TBL] [Abstract][Full Text] [Related]
10. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.
Weber AA; Schrör K
Blood; 2001 Sep; 98(5):1619-21. PubMed ID: 11520817
[TBL] [Abstract][Full Text] [Related]
11. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
[TBL] [Abstract][Full Text] [Related]
12. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
[TBL] [Abstract][Full Text] [Related]
13. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
Quinn M; Deering A; Stewart M; Cox D; Foley B; Fitzgerald D
Circulation; 1999 May; 99(17):2231-8. PubMed ID: 10226086
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
Keating FK; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
Abernethy DR; Pezzullo J; Mascelli MA; Frederick B; Kleiman NS; Freedman J
Clin Pharmacol Ther; 2002 Mar; 71(3):186-95. PubMed ID: 11907493
[TBL] [Abstract][Full Text] [Related]
16. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model.
Klinkhardt U; Graff J; Harder S
Clin Pharmacol Ther; 2002 Mar; 71(3):176-85. PubMed ID: 11907492
[TBL] [Abstract][Full Text] [Related]
17. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia.
Mak KH; Kottke-Marchant K; Brooks LM; Topol EJ
Thromb Haemost; 1998 Dec; 80(6):989-93. PubMed ID: 9869172
[TBL] [Abstract][Full Text] [Related]
18. Platelet glycoprotein IIb/IIIa receptor antagonist (abciximab) inhibited platelet activation and promoted skin flap survival after ischemia/reperfusion injury.
Kuo YR; Jeng SF; Wang FS; Huang HC; Wei FC; Yang KD
J Surg Res; 2002 Sep; 107(1):50-5. PubMed ID: 12384064
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
Klinkhardt U; Kirchmaier CM; Westrup D; Graff J; Mahnel R; Breddin HK; Harder S
Clin Pharmacol Ther; 2000 Mar; 67(3):305-13. PubMed ID: 10741635
[TBL] [Abstract][Full Text] [Related]
20. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression.
Steiner S; Seidinger D; Huber K; Kaun C; Minar E; Kopp CW
Arterioscler Thromb Vasc Biol; 2003 Sep; 23(9):1697-702. PubMed ID: 12869353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
